Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Myeloid Leukemia, Acute: early-phase trial registry
3 of 4 indexed Myeloid Leukemia, Acute trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #4,115 of 28,707 conditions by registered trial count.
4 US clinical trials · 3 currently recruiting · #4,115 of 28,707 conditions by registered trial count
Myeloid Leukemia, Acute: 4 US clinical trials tracked, 3 recruiting.
Myeloid Leukemia, Acute is the subject of 4 registered US clinical trials on ClinicalTrials.gov, 3 of them currently open to new participants. 1 are in Phase 3-4 (later-stage) and 2 in Phase 1-2 (earlier-stage). The most active sponsor is Actinium Pharmaceuticals, running 1 of these trials.
Enrollment posture brief
Registry condition myeloid-leukemia-acute
OPEN 3 | RECR 75% | LATE 1 | EARLY 2 | RANK #4115 | SPON 1
Volume-matched condition peers
Nearest open-share peer: Activity, Motor (75% recruiting · 8 trials)
Myeloid Leukemia, Acute lists 3 open slots (75% of 4 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Myeloid Leukemia, Acute on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Myeloid Leukemia, Acute is recruiting above its size-band peers.
3 of 4 indexed trials (75%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
Open and recent trials
4 total, page 1 of 1
A Decisional Intervention for Older Adults With Acute Myeloid Leukemia and Their Caregivers
University of Rochester
NCT06697600
Autologous T Cells Transduced With Retroviral Vectors Expressing TCRs for Participant-specific Neoantigens in Patients With Hematologic Malignancies
National Cancer Institute (NCI)
NCT06904066
IS-free Treg HaploHCT
Dana-Farber Cancer Institute
NCT04678401
Study of Iomab-B vs. Conventional Care in Older Subjects With Active, Relapsed or Refractory Acute Myeloid Leukemia
Actinium Pharmaceuticals
NCT02665065
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 2 |
| Phase 3 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on Myeloid Leukemia, Acute records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Myeloid Leukemia, Acute trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Myeloid Leukemia, Acute page
4 registered trials, 3 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 3 Myeloid Leukemia, Acute trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Actinium Pharmaceuticals sponsors the most Myeloid Leukemia, Acute trials on record, review their full trial history before evaluating a specific study. See Actinium Pharmaceuticals's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Myeloid Leukemia, Acute condition card totals 4 registered trials; most-linked intervention HCT; top US site state New York. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.